- Home
- RXST vs DTIL Comparison
RXST vs DTIL Comparison
Compare RXST & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXST | DTIL |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.6M | 197.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RXST | DTIL |
|---|---|---|
| Price | $4.57 | $6.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $7.57 | ★ $29.40 |
| AVG Volume (30 Days) | ★ 728.6K | 253.5K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.45 | $3.53 |
| 52 Week High | $13.22 | $9.62 |
Technical Indicators
Market Signals| Indicator | RXST | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 31.38 | 37.19 |
| Support Level | N/A | $6.00 |
| Resistance Level | $4.99 | $7.55 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 8.26 | 7.94 |
Price Performance
Historical ComparisonAbout RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).